TransMedics Group, Inc. - 10-Q Filing

TransMedics Group, Inc. reports Q3 2025 financial results including OCS transplant revenue across lung, liver, and heart product lines.

SEC EDGAR ·

Tickers: $TMDX

Read the full article at SEC EDGAR

More Regulatory news